Narrative review / 2016
A review found no convincing evidence that amygdalin induces tumor regression in cancer patients, nor evidence of toxicity at therapeutic doses.
Researchers conducted a retrospective review of PubMed literature and authorized governmental internet sources regarding amygdalin (laetrile) use in cancer, covering pharmacokinetics, preclinical and clinical studies, and toxicity. No convincing evidence was apparent to show that amygdalin induces rapid, distinct tumor regression in cancer patients, especially those with late-stage disease. Additionally, there was no evidence that purified amygdalin causes toxicity when administered in 'therapeutic' dosage. The authors noted that multiple aspects of amygdalin administration remain inadequately explored.
- Study type
- Literature review
- Who was studied
- Cancer patients consuming amygdalin / evaluated in clinical studies
- What was measured
- Tumor regression and toxicity associated with amygdalin administration
THE PAPER
Amygdalin, quackery or cure?
Blaheta RA, Nelson K, Haferkamp A, Juengel E. Phytomedicine, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.